Eisai Inc Drug Patent Portfolio
Eisai Inc owns 9 orange book drugs protected by 58 US patents with Aricept Odt having the least patent protection, holding only 2 patents. And Belviq Xr with maximum patent protection, holding 17 patents. Given below is the list of Eisai Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090386 | Method for suppressing bitterness of quinoline derivative | 23 Aug, 2036 | Active |
| US12083112 | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer | 03 Mar, 2036 | Active |
| US10259791 | High-purity quinoline derivative and method for manufacturing same | 26 Feb, 2036 | Active |
| US10407393 | High-purity quinoline derivative and method for manufacturing same | 26 Feb, 2036 | Active |
| US11186547 | High-purity quinoline derivative and method for manufacturing same | 26 Feb, 2036 | Active |
| US11090386 | Method for suppressing bitterness of quinoline derivative | 23 Feb, 2036 | Active |
| US10188652 | Compositions and methods for treating insomnia | 21 Oct, 2035 | Active |
| US10702529 | Compositions and methods for treating insomnia | 21 Oct, 2035 | Active |
| US11026944 | Compositions and methods for treating insomnia | 21 Oct, 2035 | Active |
| US10259791 | High-purity quinoline derivative and method for manufacturing same | 26 Aug, 2035 | Active |
| US10407393 | High-purity quinoline derivative and method for manufacturing same | 26 Aug, 2035 | Active |
| US11186547 | High-purity quinoline derivative and method for manufacturing same | 26 Aug, 2035 | Active |
| US8999970 | Administration of an anti-obesity compound to individuals with renal impairment | 07 Feb, 2033 | Active |
| US9169213 | Method of weight management | 06 Dec, 2032 | Active |
| US8268848 | Cyclopropane compound | 20 Sep, 2031 | Active |
| US9770455 | Administration of an anti-obesity compound to individuals with renal impairment | 31 Aug, 2031 | Active |
| US10226471 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | 31 Aug, 2031 | Active |
| US10463676 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | 31 Aug, 2031 | Active |
| US8168624 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | 18 Apr, 2029 | Active |
| US9006256 | Antitumor agent for thyroid cancer | 27 Jan, 2028 | Active |
| US9006256 | Antitumor agent for thyroid cancer | 27 Jul, 2027 | Active |
| USRE46965 | Intermediates for the preparation of analogs of Halichondrin B | 08 Jul, 2027 | Active |
| US7612208 | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | 19 Mar, 2027 | Active |
| USRE46965 | Intermediates for the preparation of analogs of Halichondrin B | 08 Jan, 2027 | Active |
| US8481565 | Method for stabilizing anti-dementia drug | 04 Oct, 2026 | Active |
| US7612208 | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | 19 Sep, 2026 | Active |
| US7253286 | Nitrogen-containing aromatic derivatives | 24 Apr, 2026 | Active |
| US8697686 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride | 20 Dec, 2025 | Active |
| US8980881 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | 20 Dec, 2025 | Active |
| US7253286 | Nitrogen-containing aromatic derivatives | 24 Oct, 2025 | Active |
| US8946207 | Processes for preparing 3-benzazepines | 16 Jun, 2024 | Expired |
| US6214865 | Macrocyclic analogs and methods of their use and preparation | 20 Jan, 2024 | Expired |
| US7169401 | Topical skin care composition containing refined peanut oil | 18 Jul, 2023 | Expired |
| US6740669 | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic | 14 May, 2023 | Expired |
| US6953787 | 5HT2C receptor modulators | 10 Apr, 2023 | Expired |
| US7514422 | 5HT2c receptor modulators | 10 Apr, 2023 | Expired |
| US7977329 | 5HT2C receptor modulators | 10 Apr, 2023 | Expired |
| US8207158 | 5HT2c receptor modulators | 10 Apr, 2023 | Expired |
| US8273734 | 5HT2C receptor modulators | 10 Apr, 2023 | Expired |
| US8367657 | Processes for preparing 3-benzazepines | 10 Apr, 2023 | Expired |
| US8546379 | 5HT2C receptor modulators | 10 Apr, 2023 | Expired |
| US8575149 | 5HT2C receptor modulators | 10 Apr, 2023 | Expired |
| US6740669 | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic | 14 Nov, 2022 | Expired |
| US6204257 | Water soluble prodrugs of hindered alcohols | 01 Jul, 2022 | Expired |
| US7727548 | Rapidly disintegrable tablet containing polyvinyl alcohol | 23 Jun, 2022 | Expired |
| US8097648 | Methods and compositions for use in treating cancer | 22 Jan, 2021 | Expired |
| US6214865 | Macrocyclic analogs and methods of their use and preparation | 16 Jun, 2019 | Expired |
| US6469182 | Intermediates in the preparation of macrocyclic analogs | 16 Jun, 2019 | Expired |
| US7470720 | Methods and compositions for use in treating cancer | 16 Jun, 2019 | Expired |
| US7750028 | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide | 19 Apr, 2019 | Expired |
| US8076362 | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof | 08 Dec, 2018 | Expired |
| US6245911 | Donepezil polycrystals and process for producing the same | 01 Dec, 2018 | Expired |
| US7750028 | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide | 19 Oct, 2018 | Expired |
| US6872838 | Water soluble prodrugs of hindered alcohols | 07 Aug, 2018 | Expired |
| US8076362 | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof | 08 Jun, 2018 | Expired |
| US7727552 | Oral pharmaceutical preparations decreased in bitterness by masking | 26 Mar, 2018 | Expired |
| US5985864 | Polymorphs of donepezil hydrochloride and process for production | 30 Dec, 2016 | Expired |
| US6140321 | Polymorphs of donepezil hydrochloride and process for production | 30 Dec, 2016 | Expired |
Latest Legal Activities on Eisai Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eisai Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 13 May, 2024 | US8273734 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 13 May, 2024 | US8273734 (Litigated) |
|
Interim Patent Term Extension Granted
Critical
| 21 Mar, 2024 | US6953787 (Litigated) |
|
Interim Patent Term Extension Granted
Critical
| 21 Mar, 2024 | US6953787 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Mar, 2024 | US8268848 |
|
Expire Patent
Critical
| 19 Feb, 2024 | US8097648 |
|
Maintenance Fee Reminder Mailed
Critical
| 12 Feb, 2024 | US8207158 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 12 Feb, 2024 | US8207158 (Litigated) |
| Post Issue Communication - Certificate of Correction | 04 Jan, 2024 | US8168624 |
| Post Issue Communication - Certificate of Correction | 04 Jan, 2024 | US8168624 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Dec, 2023 | US10702529 |
|
PTE Interim Patent Extension filed
Critical
| 21 Dec, 2023 | US6953787 (Litigated) |
| Requirement for information sent under 37 CFR 1.750 | 21 Dec, 2023 | US6953787 (Litigated) |
| Requirement for information sent under 37 CFR 1.750 | 21 Dec, 2023 | US6953787 (Litigated) |
|
PTE Interim Patent Extension filed
Critical
| 21 Dec, 2023 | US6953787 (Litigated) |
Eisai Inc's Drug Patent Litigations
Eisai Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 22, 2003, against patent number US6740669. The petitioner , challenged the validity of this patent, with ROBERT PORTMANN et al as the respondent. Click below to track the latest information on how companies are challenging Eisai Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6740669 | April, 2003 |
Decision
(17 Nov, 2003)
| ROBERT PORTMANN et al | |
Eisai Inc Drug Patents' Oppositions Filed in EPO
Eisai Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 18, 2016, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP07743994A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP19151846A | May, 2023 | Welding GmbH & Co. KG | Granted and Under Opposition |
| EP19151846A | May, 2023 | Accord Healthcare | Granted and Under Opposition |
| EP19151846A | May, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP19151846A | May, 2023 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP19151846A | May, 2023 | Aechter, Bernd | Granted and Under Opposition |
| EP19151846A | May, 2023 | Maiwald GmbH | Granted and Under Opposition |
| EP19151846A | May, 2023 | Hansen, Norbert | Granted and Under Opposition |
| EP19151846A | May, 2023 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP19151846A | May, 2023 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP07743994A | Jul, 2016 | Generics [UK] Ltd (trading as Mylan) | Revoked |
| EP07743994A | Jul, 2016 | Actavis Group PTC ehf | Revoked |
Eisai Inc's Family Patents
Eisai Inc Drug List
Given below is the complete list of Eisai Inc's drugs and the patents protecting them.
1. Aricept
Aricept is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8481565 | Method for stabilizing anti-dementia drug |
04 Oct, 2026
(1 year, 9 months from now)
| Active |
| US6245911 | Donepezil polycrystals and process for producing the same |
01 Dec, 2018
(6 years ago)
| Expired |
| US5985864 | Polymorphs of donepezil hydrochloride and process for production |
30 Dec, 2016
(7 years ago)
| Expired |
| US6140321 | Polymorphs of donepezil hydrochloride and process for production |
30 Dec, 2016
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aricept's drug page
2. Aricept Odt
Aricept Odt is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7727548 | Rapidly disintegrable tablet containing polyvinyl alcohol |
23 Jun, 2022
(2 years ago)
| Expired |
| US7727552 | Oral pharmaceutical preparations decreased in bitterness by masking |
26 Mar, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aricept Odt's drug page
3. Banzel
Banzel is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6740669
(Pediatric)
| Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
14 May, 2023
(1 year, 6 months ago)
| Expired |
| US6740669 | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
14 Nov, 2022
(2 years ago)
| Expired |
| US7750028
(Pediatric)
| Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
19 Apr, 2019
(5 years ago)
| Expired |
| US8076362
(Pediatric)
| Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
08 Dec, 2018
(5 years ago)
| Expired |
| US7750028 | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
19 Oct, 2018
(6 years ago)
| Expired |
| US8076362 | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
08 Jun, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Banzel's drug page
4. Belviq
Belviq is protected by 16 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8999970 | Administration of an anti-obesity compound to individuals with renal impairment |
07 Feb, 2033
(8 years from now)
| Active |
| US9169213 | Method of weight management |
06 Dec, 2032
(8 years from now)
| Active |
| US9770455 | Administration of an anti-obesity compound to individuals with renal impairment |
31 Aug, 2031
(6 years from now)
| Active |
| US8168624 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
18 Apr, 2029
(4 years from now)
| Active |
| US8697686 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
20 Dec, 2025
(1 year, 16 days from now)
| Active |
| US8980881 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
20 Dec, 2025
(1 year, 16 days from now)
| Active |
| US8946207 | Processes for preparing 3-benzazepines |
16 Jun, 2024
(5 months ago)
| Expired |
| US7169401 | Topical skin care composition containing refined peanut oil |
18 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US6953787 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7514422 | 5HT2c receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7977329 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8207158 | 5HT2c receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8273734 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8367657 | Processes for preparing 3-benzazepines |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8546379 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8575149 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belviq's drug page
5. Belviq Xr
Belviq Xr is protected by 17 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8999970 | Administration of an anti-obesity compound to individuals with renal impairment |
07 Feb, 2033
(8 years from now)
| Active |
| US9169213 | Method of weight management |
06 Dec, 2032
(8 years from now)
| Active |
| US10226471 | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
31 Aug, 2031
(6 years from now)
| Active |
| US10463676 | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
31 Aug, 2031
(6 years from now)
| Active |
| US9770455 | Administration of an anti-obesity compound to individuals with renal impairment |
31 Aug, 2031
(6 years from now)
| Active |
| US8168624 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
18 Apr, 2029
(4 years from now)
| Active |
| US8697686 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
20 Dec, 2025
(1 year, 16 days from now)
| Active |
| US8980881 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
20 Dec, 2025
(1 year, 16 days from now)
| Active |
| US8946207 | Processes for preparing 3-benzazepines |
16 Jun, 2024
(5 months ago)
| Expired |
| US6953787 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7514422 | 5HT2c receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US7977329 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8207158 | 5HT2c receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8273734 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8367657 | Processes for preparing 3-benzazepines |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8546379 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
| US8575149 | 5HT2C receptor modulators |
10 Apr, 2023
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belviq Xr's drug page
Explore Our Curated Drug Screens
6. Dayvigo
Dayvigo is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10188652 | Compositions and methods for treating insomnia |
21 Oct, 2035
(10 years from now)
| Active |
| US10702529 | Compositions and methods for treating insomnia |
21 Oct, 2035
(10 years from now)
| Active |
| US11026944 | Compositions and methods for treating insomnia |
21 Oct, 2035
(10 years from now)
| Active |
| US8268848 | Cyclopropane compound |
20 Sep, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dayvigo's drug page
7. Halaven
Halaven is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE46965
(Pediatric)
| Intermediates for the preparation of analogs of Halichondrin B |
08 Jul, 2027
(2 years from now)
| Active |
| USRE46965 | Intermediates for the preparation of analogs of Halichondrin B |
08 Jan, 2027
(2 years from now)
| Active |
| US6214865
(Pediatric)
| Macrocyclic analogs and methods of their use and preparation |
20 Jan, 2024
(10 months ago)
| Expired |
| US8097648 | Methods and compositions for use in treating cancer |
22 Jan, 2021
(3 years ago)
| Expired |
| US6214865 | Macrocyclic analogs and methods of their use and preparation |
16 Jun, 2019
(5 years ago)
| Expired |
| US6469182 | Intermediates in the preparation of macrocyclic analogs |
16 Jun, 2019
(5 years ago)
| Expired |
| US7470720 | Methods and compositions for use in treating cancer |
16 Jun, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Halaven's drug page
8. Lenvima
Lenvima is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090386
(Pediatric)
| Method for suppressing bitterness of quinoline derivative |
23 Aug, 2036
(11 years from now)
| Active |
| US12083112 | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
03 Mar, 2036
(11 years from now)
| Active |
| US10259791
(Pediatric)
| High-purity quinoline derivative and method for manufacturing same |
26 Feb, 2036
(11 years from now)
| Active |
| US10407393
(Pediatric)
| High-purity quinoline derivative and method for manufacturing same |
26 Feb, 2036
(11 years from now)
| Active |
| US11186547
(Pediatric)
| High-purity quinoline derivative and method for manufacturing same |
26 Feb, 2036
(11 years from now)
| Active |
| US11090386 | Method for suppressing bitterness of quinoline derivative |
23 Feb, 2036
(11 years from now)
| Active |
| US10259791 | High-purity quinoline derivative and method for manufacturing same |
26 Aug, 2035
(10 years from now)
| Active |
| US10407393 | High-purity quinoline derivative and method for manufacturing same |
26 Aug, 2035
(10 years from now)
| Active |
| US11186547 | High-purity quinoline derivative and method for manufacturing same |
26 Aug, 2035
(10 years from now)
| Active |
| US9006256
(Pediatric)
| Antitumor agent for thyroid cancer |
27 Jan, 2028
(3 years from now)
| Active |
| US9006256 | Antitumor agent for thyroid cancer |
27 Jul, 2027
(2 years from now)
| Active |
| US7612208
(Pediatric)
| Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
19 Mar, 2027
(2 years from now)
| Active |
| US7612208 | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
19 Sep, 2026
(1 year, 9 months from now)
| Active |
| US7253286
(Pediatric)
| Nitrogen-containing aromatic derivatives |
24 Apr, 2026
(1 year, 4 months from now)
| Active |
| US7253286 | Nitrogen-containing aromatic derivatives |
24 Oct, 2025
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lenvima's drug page
9. Lusedra
Lusedra is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6204257 | Water soluble prodrugs of hindered alcohols |
01 Jul, 2022
(2 years ago)
| Expired |
| US6872838 | Water soluble prodrugs of hindered alcohols |
07 Aug, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lusedra's drug page